Baird cuts Dyne Therapeutics price target to $26 from $30
Baird cut its Dyne Therapeutics price target to $26.00 per share from $30.00, per Benzinga ratings actions.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.